The improved specificity that PROTACs show for BRD4, unlike traditional BET protein inhibitors which show comparable affinity for BRD2, 3 and 4, highlights the therapeutic application that BRD4-PROTACs may have in the treatment of cancer, such as MM and AML, for which this isoform is specifically implicated. This evidence concerns the gene BRD4 and Miyoshi myopathy.